Children's Health Defense Two new reports raise concerns about the dangers of Beyfortus, an immunization against RSV for infants that the Centers for Disease Control and Prevention added last year to the Childhood Immunization Schedule.
Infants treated for RSV with the monoclonal antibody nirsevimab have significantly higher mortality rates than those treated with a different monoclonal antibody or with a placebo, according to an analysis by the Japanese journal Med Check of three major randomized control trials.
The report reanalyzed clinical trial data showing that nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — reduced RSV-associated lower respiratory tract infection and hospitalizations in both high-risk and healthy infants.
However, babies treated with the drug had a higher mortality rate likely linked to adverse effects — including thrombosis (blood clotting) — from the drug itself, the study found.
“Due to the increased mortality, nirsevimab should not be used in any infants,” the study concluded. “Do not use nirsevimab for universal immunization.”
…
Read Full Article Here…(childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
